R. Jaspe, Y. Sulbarn, C. Loureiro, Pierina DAngelo, L. Rodríguez, D. Garzaro, H. Rangel, F. Pujol
Variants of Concern of SARS-CoV-2 (VOCs), the new coronavirus responsible for COVID-19, have emerged in several countries. Mutations in the amino acid 484 of the Spike protein are particularly important and associated with some of these variants: E484K or E484Q. These mutations have been associated with evasion to neutralizing antibodies. Restriction enzyme analysis is proposed as a rapid method to detect these mutations. A search on GISAID was performed in April 2021 to detect the frequency of these two mutations in the sequence available and their association with other lineages. E484K, present in some VOCs, has emerged in several other lineages and is frequently found in recent viral isolates. A small amplicon from the Spike gene was digested with two enzymes: HpyAV, and MseI. The use of these two enzymes allows the detection of mutations at position 484, and to differentiate between these three conditions: non-mutated, and the presence of E484K or E484Q. A 100% correlation was observed with sequencing results. The proposed methodology, which allows for the screening of a great number of samples, will probably help to provide more information on the prevalence and epidemiology of these mutations worldwide, to select the candidates for whole-genome sequencing.
{"title":"Importance of mutations in amino acid 484 of the Spike protein of SARS-CoV-2: rapid detection by restriction enzyme analysis","authors":"R. Jaspe, Y. Sulbarn, C. Loureiro, Pierina DAngelo, L. Rodríguez, D. Garzaro, H. Rangel, F. Pujol","doi":"10.22209/IC.v62s2a02","DOIUrl":"https://doi.org/10.22209/IC.v62s2a02","url":null,"abstract":"Variants of Concern of SARS-CoV-2 (VOCs), the new coronavirus responsible for COVID-19, have emerged in several countries. Mutations in the amino acid 484 of the Spike protein are particularly important and associated with some of these variants: E484K or E484Q. These mutations have been associated with evasion to neutralizing antibodies. Restriction enzyme analysis is proposed as a rapid method to detect these mutations. A search on GISAID was performed in April 2021 to detect the frequency of these two mutations in the sequence available and their association with other lineages. E484K, present in some VOCs, has emerged in several other lineages and is frequently found in recent viral isolates. A small amplicon from the Spike gene was digested with two enzymes: HpyAV, and MseI. The use of these two enzymes allows the detection of mutations at position 484, and to differentiate between these three conditions: non-mutated, and the presence of E484K or E484Q. A 100% correlation was observed with sequencing results. The proposed methodology, which allows for the screening of a great number of samples, will probably help to provide more information on the prevalence and epidemiology of these mutations worldwide, to select the candidates for whole-genome sequencing.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41560411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Stulin, M. Oca, G. Blanco, L. Sanchez, Isabel Marcolino da Silva, J. Quevedo, M. C. Arvelo, N. Valera, I. Papa, F. D. Abreu, H. Villarroel, J. C. Catari, J. López, B. Moran, C. Cárdenas, S. Santucci, J. Viloria, J. G. C. Gomez, A. Martinelli, E. García, M. Guzman
Hyperglycemia, with or without diabetes, is associated with complications in hospitalized patients with COVID-19. There is no information regarding this problem in our region. This study was aimed to compare the characteristics and in-hospital clinical course of patients with a probable diagnosis of COVID-19, with and without hyperglycemia during the hospitalization. This is a retrospective, observational study of clinical records review of hospitalized patients with COVID-19. The ISARIC-WHO form was used for data collection. Hyperglycemia was defined as a fasting value >= 140 mg/dL according to standard glycaemia targets in hospitalized patients. A total of 148 patients were included, 97 (65.5%) men and 51 (34.5%) women, with a mean age of 64.1 +/- 16.1 years;of which 42/148 (28.4%) patients reported previous diabetes, 60/148 (40.5%) patients had hyperglycemia during the hospitalization and 32/60 (53.3%) of these cases did not report previous diabetes. The patients with hyperglycemia were older, received more frequently systemic corticosteroids (96.6 vs 82.6%;p=0.01), and antibiotics (68.3 vs 44.3%;p=0.01), had worse baseline oxygenation parameters (SpO(2) 88.1 +/- 1,1.7%;vs 92.8 +/- 5.5%;p=0.02, PaO2/FiO(2), 194.4 +/- 119.7 vs 270.9 +/- 118.3;p<0.001), higher total lung severity score in the chest CT (14.9 +/- 5.7 vs 11.1 +/- 6.3;p<0.001) and higher levels of baseline inflammatory markers (CRP 6.73 +/- 3.61 vs 5.08 +/- 4.21;p<0.01, LDH 342.9 +/- 118.4 vs 296.5 +/- 161.4;p=0.01 and Ferritin 687.7 +/- 373.2 vs 542.6 +/- 395.3;p=0.01). Mortality (34.5 vs 10.7%;p<0.001) and admission to ICU (43.3 vs 7.9%;p<0.001) were higher in patients with hyperglycemia. Hyperglycemia in hospitalized patients with COVID-19 is a marker of severe disease and poor prognosis.
COVID-19住院患者的高血糖伴或不伴糖尿病与并发症有关。我们的环境中没有关于这个问题的信息。本研究的目的是比较在住院期间出现高血糖或未出现高血糖的COVID-19患者的特点和住院临床病程。这是一项回顾性、观察性研究，回顾COVID-19住院患者的临床病史。使用ISARIC和世卫组织开发的表格收集数据。根据住院患者的标准血糖目标，它被定义为高血糖，空腹值等于或大于140 mg/ dL。我们纳入148例患者，男性97例(65.5%)，女性51例(34.5%)，平均年龄64.1±16.1岁，其中42例(28.4%)有糖尿病史，60例(40.5%)有住院高血糖史，32例(53.3%)无糖尿病史。高血糖患者年龄较大，全身皮质类固醇治疗较多(96.6 vs 82.6%;p= 0.01)，抗生素(68.3 vs 44.3%;p= 0.01)，进入氧合变化较大(SpO2 88.1±11.7% vs 92.8±5.5%，p= 0.02;PaO2/FiO2, 1940.4±119.7 vs 270.9±118.3,p< 0.001)，胸部ct肺损伤扩展评分较高(14.9±5.7 vs 11.1±6.3;p< 0.001)和炎症标志物改变最多(crp 6.73±3.61 vs 5.08±4.21;p< 0.01, LDH 342.9±118.4 vs 296.5±161.4;p= 0.01，铁蛋白687.7±373.2 vs 542.6±395.3;p = 0.01)。死亡率(34.5 vs 10.7%;p< 0.001)和icu入院(43.3 vs 7.9%;p< 0.001)在高血糖患者中较高。COVID-19住院患者的高血糖是最严重和预后差的标志。
{"title":"Caracterización clínica, según niveles de glucemia, de pacientes hospitalizados por COVID-19: serie de casos","authors":"I. Stulin, M. Oca, G. Blanco, L. Sanchez, Isabel Marcolino da Silva, J. Quevedo, M. C. Arvelo, N. Valera, I. Papa, F. D. Abreu, H. Villarroel, J. C. Catari, J. López, B. Moran, C. Cárdenas, S. Santucci, J. Viloria, J. G. C. Gomez, A. Martinelli, E. García, M. Guzman","doi":"10.22209/IC.v62s2a03","DOIUrl":"https://doi.org/10.22209/IC.v62s2a03","url":null,"abstract":"Hyperglycemia, with or without diabetes, is associated with complications in hospitalized patients with COVID-19. There is no information regarding this problem in our region. This study was aimed to compare the characteristics and in-hospital clinical course of patients with a probable diagnosis of COVID-19, with and without hyperglycemia during the hospitalization. This is a retrospective, observational study of clinical records review of hospitalized patients with COVID-19. The ISARIC-WHO form was used for data collection. Hyperglycemia was defined as a fasting value >= 140 mg/dL according to standard glycaemia targets in hospitalized patients. A total of 148 patients were included, 97 (65.5%) men and 51 (34.5%) women, with a mean age of 64.1 +/- 16.1 years;of which 42/148 (28.4%) patients reported previous diabetes, 60/148 (40.5%) patients had hyperglycemia during the hospitalization and 32/60 (53.3%) of these cases did not report previous diabetes. The patients with hyperglycemia were older, received more frequently systemic corticosteroids (96.6 vs 82.6%;p=0.01), and antibiotics (68.3 vs 44.3%;p=0.01), had worse baseline oxygenation parameters (SpO(2) 88.1 +/- 1,1.7%;vs 92.8 +/- 5.5%;p=0.02, PaO2/FiO(2), 194.4 +/- 119.7 vs 270.9 +/- 118.3;p<0.001), higher total lung severity score in the chest CT (14.9 +/- 5.7 vs 11.1 +/- 6.3;p<0.001) and higher levels of baseline inflammatory markers (CRP 6.73 +/- 3.61 vs 5.08 +/- 4.21;p<0.01, LDH 342.9 +/- 118.4 vs 296.5 +/- 161.4;p=0.01 and Ferritin 687.7 +/- 373.2 vs 542.6 +/- 395.3;p=0.01). Mortality (34.5 vs 10.7%;p<0.001) and admission to ICU (43.3 vs 7.9%;p<0.001) were higher in patients with hyperglycemia. Hyperglycemia in hospitalized patients with COVID-19 is a marker of severe disease and poor prognosis.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47872273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. V. Cepeda, Juan C. Jiménez, F. Pujol, H. Rangel, C. Bello, José Cubillan, M. L. Serrano, T. Chacón, Antonietta Saba, M. López, A. Rodríguez-Acosta
Emerging viruses such as the COVID-19-inducing virus, SARSCoV- 2, represent a threat to human health, unless effective vaccines, drugs or alternative treatments, such as passive immunization, become accessible. Animal-derived immunoglobulins, such as equine immunoglobulins might be useful as immunoprophylaxis or immunotherapy against this viral disease. Therapeutic antibodies (Abs) for SARS-CoV-2 were obtained from hyperimmune equine plasma using the Spike protein receptor binding domain (RBD) as an immunogen. The presence of anti-RBD antibodies was evaluated by ELISA and the titres of neutralizing antibodies were determined in viral cell culture. Immunized horses generated high-titre of anti-RBD antibodies with antiviral neutralizing activity on Vero-E6 cells of 1/1,000. To minimize potential adverse effects, the immunoglobulins were digested with pepsin, and purified to obtain the F(ab’)2 fragments with the protocol standardized by Biotecfar C.A for the production of snake antivenom. Pre-immune serum displayed an unexpected anti-RBD reactivity by ELISA (titre up to 1/900) and Western Blot, but no angioneutralizing activity. Modelling of the RBD of equine coronavirus showed that some of the known epitopes of SARS-CoV-2 RBD were structurally conserved in the equine coronavirus protein. This might suggest that some of the reactivity observed in the pre-immune serum to the SARS-CoV-2 RBD might be due to a previous exposure to equine coronavirus.
{"title":"Production of equine sera as a potential immunotherapy against COVID-19","authors":"M. V. Cepeda, Juan C. Jiménez, F. Pujol, H. Rangel, C. Bello, José Cubillan, M. L. Serrano, T. Chacón, Antonietta Saba, M. López, A. Rodríguez-Acosta","doi":"10.22209/IC.v62s2a01","DOIUrl":"https://doi.org/10.22209/IC.v62s2a01","url":null,"abstract":"Emerging viruses such as the COVID-19-inducing virus, SARSCoV- 2, represent a threat to human health, unless effective vaccines, drugs or alternative treatments, such as passive immunization, become accessible. Animal-derived immunoglobulins, such as equine immunoglobulins might be useful as immunoprophylaxis or immunotherapy against this viral disease. Therapeutic antibodies (Abs) for SARS-CoV-2 were obtained from hyperimmune equine plasma using the Spike protein receptor binding domain (RBD) as an immunogen. The presence of anti-RBD antibodies was evaluated by ELISA and the titres of neutralizing antibodies were determined in viral cell culture. Immunized horses generated high-titre of anti-RBD antibodies with antiviral neutralizing activity on Vero-E6 cells of 1/1,000. To minimize potential adverse effects, the immunoglobulins were digested with pepsin, and purified to obtain the F(ab’)2 fragments with the protocol standardized by Biotecfar C.A for the production of snake antivenom. Pre-immune serum displayed an unexpected anti-RBD reactivity by ELISA (titre up to 1/900) and Western Blot, but no angioneutralizing activity. Modelling of the RBD of equine coronavirus showed that some of the known epitopes of SARS-CoV-2 RBD were structurally conserved in the equine coronavirus protein. This might suggest that some of the reactivity observed in the pre-immune serum to the SARS-CoV-2 RBD might be due to a previous exposure to equine coronavirus.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48097851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José Manuel Barboza-Vílchez, Jormany Quintero-Rojas, Angélica Sivira-Penott, Lenín Constantino Valeri-Ramírez, E. Rosa, Ciro Antonio Angulo-Lacruz
En diciembre de 2019 comenzó en China la enfermedad por coronavirus COVID-19. Desde entonces se han reportado millones de infecciones y decesos por esta causa a nivel mundial, particularmente entre los trabajadores de salud quienes han sufrido el duro embate de la pandemia en el contexto de sistemas sanitarios colapsados por la demanda. En este sentido el objetivo de este trabajo fue determinar la prevalencia, características sociodemográficas, epidemiológicas y clínicas de la COVID-19 presentes en el personal del Instituto Autónomo Hospital Universitario de Los Andes en Mérida-Venezuela. Se realizó un estudio observacional, retrospectivo, unicéntrico y documental, donde se analizaron 297 fichas clínico-epidemiológicas correspondientes a 285 empleados, en un periodo comprendido entre el 16 de marzo y el 30 de noviembre de 2020. Los registros se separaron en dos grupos, trabajadores de primera línea y trabajadores de apoyo. La positividad general de las RT-PCR realizadas fue del 31,6%. La frecuencia de los resultados confirmatorios positivos fue mayor entre los trabajadores de apoyo con un 33,9%. El personal de enfermería fue el que presentó mayor positividad (39,5%). Se halló una seroprevalencia del 34,3% en las pruebas inmunológicas. La prevalencia de la infección por SARS-CoV-2 entre el personal se presentó con mayor frecuencia en quienes laboran en actividades de apoyo, en comparación con aquellos de primera línea. Por tanto, deben fortalecerse las estrategias de prevención generales y laborales específicas, y así limitar la diseminación del SARS-CoV-2 entre el personal, para que este se desempeñe de manera segura y efectiva.
{"title":"COVID-19 en los trabajadores de salud del Instituto Autónomo Hospital Universitario de Los Andes en Mérida, Venezuela","authors":"José Manuel Barboza-Vílchez, Jormany Quintero-Rojas, Angélica Sivira-Penott, Lenín Constantino Valeri-Ramírez, E. Rosa, Ciro Antonio Angulo-Lacruz","doi":"10.22209/IC.v62s2a04","DOIUrl":"https://doi.org/10.22209/IC.v62s2a04","url":null,"abstract":"En diciembre de 2019 comenzó en China la enfermedad por coronavirus COVID-19. Desde entonces se han reportado millones de infecciones y decesos por esta causa a nivel mundial, particularmente entre los trabajadores de salud quienes han sufrido el duro embate de la pandemia en el contexto de sistemas sanitarios colapsados por la demanda. En este sentido el objetivo de este trabajo fue determinar la prevalencia, características sociodemográficas, epidemiológicas y clínicas de la COVID-19 presentes en el personal del Instituto Autónomo Hospital Universitario de Los Andes en Mérida-Venezuela. Se realizó un estudio observacional, retrospectivo, unicéntrico y documental, donde se analizaron 297 fichas clínico-epidemiológicas correspondientes a 285 empleados, en un periodo comprendido entre el 16 de marzo y el 30 de noviembre de 2020. Los registros se separaron en dos grupos, trabajadores de primera línea y trabajadores de apoyo. La positividad general de las RT-PCR realizadas fue del 31,6%. La frecuencia de los resultados confirmatorios positivos fue mayor entre los trabajadores de apoyo con un 33,9%. El personal de enfermería fue el que presentó mayor positividad (39,5%). Se halló una seroprevalencia del 34,3% en las pruebas inmunológicas. La prevalencia de la infección por SARS-CoV-2 entre el personal se presentó con mayor frecuencia en quienes laboran en actividades de apoyo, en comparación con aquellos de primera línea. Por tanto, deben fortalecerse las estrategias de prevención generales y laborales específicas, y así limitar la diseminación del SARS-CoV-2 entre el personal, para que este se desempeñe de manera segura y efectiva.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46744969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Mosquera-Sulbaran, A. Pedreáñez, D. Callejas, Yenddy Carrero
Las tetraciclinas se han utilizado para tratar muchas infecciones bacterianas. El uso de estos antibióticos para el tratamiento de enfermedades virales se remonta a las décadas de 1960 y 1970. Estudios posteriores han demostrado la eficacia de las tetraciclinas como fármaco antiviral en modelos experimentales y estudios in vitro. Las tetraciclinas pueden actuar sobre las infecciones virales por diversos mecanismos, en los que se incluyen: capacidad de inhibir las metaloproteinasas, efectos antinflamatorios, inhibición de la vía NF-kB, efecto anti-apoptótico y antioxidante, inhibición de síntesis de proteínas, inhibición de proteínas estructurales, de proteasas y ARN virales, entre otras propiedades. De esta manera, las tetraciclinas representan un potencial fármaco contra la infección por el SARS-CoV-2. A pesar del potencial de las tetraciclinas como fármacos antivirales, se requieren más estudios clínicos. Es importante desarrollar tratamientos antivirales para el COVID-19, que puedan administrarse en una fase temprana de la infección, con el fin de evitar el daño orgánico causado por el virus y permitir que el paciente produzca una fuerte respuesta inmunitaria. Esta revisión se centra en los datos clínicos y experimentales que apoyan el uso de tetraciclina en el tratamiento de las infecciones virales y destaca un enfoque importante para frenar la progresión de la enfermedad durante la infección viral. El tratamiento con tetraciclina podría representar una estrategia para eliminar la infección o inhibir la progresión de la COVID-19.
{"title":"Tetraciclinas: ¿Antibióticos de uso potencial en la COVID-19?","authors":"J. Mosquera-Sulbaran, A. Pedreáñez, D. Callejas, Yenddy Carrero","doi":"10.22209/IC.v62s2a06","DOIUrl":"https://doi.org/10.22209/IC.v62s2a06","url":null,"abstract":"Las tetraciclinas se han utilizado para tratar muchas infecciones bacterianas. El uso de estos antibióticos para el tratamiento de enfermedades virales se remonta a las décadas de 1960 y 1970. Estudios posteriores han demostrado la eficacia de las tetraciclinas como fármaco antiviral en modelos experimentales y estudios in vitro. Las tetraciclinas pueden actuar sobre las infecciones virales por diversos mecanismos, en los que se incluyen: capacidad de inhibir las metaloproteinasas, efectos antinflamatorios, inhibición de la vía NF-kB, efecto anti-apoptótico y antioxidante, inhibición de síntesis de proteínas, inhibición de proteínas estructurales, de proteasas y ARN virales, entre otras propiedades. De esta manera, las tetraciclinas representan un potencial fármaco contra la infección por el SARS-CoV-2. A pesar del potencial de las tetraciclinas como fármacos antivirales, se requieren más estudios clínicos. Es importante desarrollar tratamientos antivirales para el COVID-19, que puedan administrarse en una fase temprana de la infección, con el fin de evitar el daño orgánico causado por el virus y permitir que el paciente produzca una fuerte respuesta inmunitaria. Esta revisión se centra en los datos clínicos y experimentales que apoyan el uso de tetraciclina en el tratamiento de las infecciones virales y destaca un enfoque importante para frenar la progresión de la enfermedad durante la infección viral. El tratamiento con tetraciclina podría representar una estrategia para eliminar la infección o inhibir la progresión de la COVID-19.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41853361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Editorial: Experiencias y propuestas sobre CoVID-19/ SARS-CoV-2 en Venezuela","authors":"","doi":"10.22209/ic.v62s2a00","DOIUrl":"https://doi.org/10.22209/ic.v62s2a00","url":null,"abstract":"","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68210014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of the present study was to evaluate the relationship between febrile convulsion, serum iron levels and whole blood parameters. This cross-sectional case-control study included patients aged 6 months-6 years-old brought to the department of pediatrics of Kütahya ParkHayat Hospital with febrile convulsions between January 2015 and December 2019. The patients were divided into two groups as: febrile with convulsions (study group; n= 47) and febrile without convulsions (control group; n= 35). Both groups were age and sex-matched. Some blood parameters such as mean serum iron, ferritin, Hb and MCV levels were used to compare the groups. Mean serum iron levels of the study and control groups were 33.7 ± 2.1 μg/dL and 56.3 ± 7.4 μg/dL (p<0.05), and serum ferritin levels were 27.3 ± 6.2 ng/mL and 31.1 ± 2.1 ng/ mL (p>0.05), respectively. Mean hemoglobin levels of the study and control groups were 10.6 ± 1.7 g/dL and 11.1 ± 1.4 g/dL (p <0.05), and mean MCV levels were 71.1 ± 1.2 fL and 73.2 ± 1.1 fL (p>0.05), respectively. In the light of the findings of this study, the low serum iron and ferritin levels may be reinforcing factors for developing febrile convulsion. However, multicentre studies with more patients are needed to reach a precise conclusion.
{"title":"Relationship between serum iron level and febrile convulsion in children","authors":"A. Kartal, Zeynep Çağla Mutlu","doi":"10.22209/ic.v62n2a02","DOIUrl":"https://doi.org/10.22209/ic.v62n2a02","url":null,"abstract":"The aim of the present study was to evaluate the relationship between febrile convulsion, serum iron levels and whole blood parameters. This cross-sectional case-control study included patients aged 6 months-6 years-old brought to the department of pediatrics of Kütahya ParkHayat Hospital with febrile convulsions between January 2015 and December 2019. The patients were divided into two groups as: febrile with convulsions (study group; n= 47) and febrile without convulsions (control group; n= 35). Both groups were age and sex-matched. Some blood parameters such as mean serum iron, ferritin, Hb and MCV levels were used to compare the groups. Mean serum iron levels of the study and control groups were 33.7 ± 2.1 μg/dL and 56.3 ± 7.4 μg/dL (p<0.05), and serum ferritin levels were 27.3 ± 6.2 ng/mL and 31.1 ± 2.1 ng/ mL (p>0.05), respectively. Mean hemoglobin levels of the study and control groups were 10.6 ± 1.7 g/dL and 11.1 ± 1.4 g/dL (p <0.05), and mean MCV levels were 71.1 ± 1.2 fL and 73.2 ± 1.1 fL (p>0.05), respectively. In the light of the findings of this study, the low serum iron and ferritin levels may be reinforcing factors for developing febrile convulsion. However, multicentre studies with more patients are needed to reach a precise conclusion.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46807064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"EDITORIAL. La fatiga crónica, la encefalomielitis miálgica/síndrome de fatiga crónica y el SARS-CoV-2","authors":"Ricardo Cárdenas","doi":"10.22209/ic.v62n2a00","DOIUrl":"https://doi.org/10.22209/ic.v62n2a00","url":null,"abstract":"","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47434520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
El “food craving” (FC) es un deseo incontrolable por ingerir alimentos en específico, se activa durante la fase de abstinencia de alimentos azucarados, salados y grasos. Se ha encontrado que se relaciona con obesi-dad (OB) y con trastornos del comportamiento de la alimentación, además de ser un factor negativo para la adherencia al tratamiento de la OB. Los Food Cravings Questionnaires Trait (T-rasgo) y State (S-estado) son instrumentos validados, que miden rasgo-estado, son confiables, y con consistencia interna alta (ɑ>0,90). El objetivo de esta investigación fue analizar diferencias entre sujetos normopeso (NP) y OB, en puntajes del FCQ Trait y State, y en la expre-sión génica de DRD2, TAS1R2, TAS1R3 y el TAS2R43. Se trató de un estudio correlacional, transversal de casos y controles, muestreo no probabilístico, y a conveniencia; con 20 sujetos NP y 20 sujetos OB, de ambos sexos entre 18-45 años, residentes de la Ciudad de México y del Estado de México. Se evaluaron el IMC, el FC y la expresión génica. Se encontraron diferencias significativas (p<0,05) en expresión relativa del TAS1R2, y correlación positiva entre el FCQ y expresión del TAS1R2 en OB; también se encontró que el FCQ-T y FCQ-S pre-dicen la expresión génica de TAS1R2 y TAS2R43 en hombres, y en mujeres del TAS1R2, TAS2R43 y el DRD2. Esta investigación ayuda a comprender la asocia-ción del FC, con el receptor del gusto dulce (TAS1R2), evidenciando el enlace con componentes moleculares, y su posible relación con adicción a alimentos azucarados.
{"title":"Asociación entre el “food craving” y los genes del gusto en personas con obesidad","authors":"María Delfina Marín-Soto, Ángel Miliar-García, Modesto Gómez-López, Ilicia González-Mundo, Víctor Ricardo Aguilera-Sosa","doi":"10.22209/ic.v62n2a03","DOIUrl":"https://doi.org/10.22209/ic.v62n2a03","url":null,"abstract":"El “food craving” (FC) es un deseo incontrolable por ingerir alimentos en específico, se activa durante la fase de abstinencia de alimentos azucarados, salados y grasos. Se ha encontrado que se relaciona con obesi-dad (OB) y con trastornos del comportamiento de la alimentación, además de ser un factor negativo para la adherencia al tratamiento de la OB. Los Food Cravings Questionnaires Trait (T-rasgo) y State (S-estado) son instrumentos validados, que miden rasgo-estado, son confiables, y con consistencia interna alta (ɑ>0,90). El objetivo de esta investigación fue analizar diferencias entre sujetos normopeso (NP) y OB, en puntajes del FCQ Trait y State, y en la expre-sión génica de DRD2, TAS1R2, TAS1R3 y el TAS2R43. Se trató de un estudio correlacional, transversal de casos y controles, muestreo no probabilístico, y a conveniencia; con 20 sujetos NP y 20 sujetos OB, de ambos sexos entre 18-45 años, residentes de la Ciudad de México y del Estado de México. Se evaluaron el IMC, el FC y la expresión génica. Se encontraron diferencias significativas (p<0,05) en expresión relativa del TAS1R2, y correlación positiva entre el FCQ y expresión del TAS1R2 en OB; también se encontró que el FCQ-T y FCQ-S pre-dicen la expresión génica de TAS1R2 y TAS2R43 en hombres, y en mujeres del TAS1R2, TAS2R43 y el DRD2. Esta investigación ayuda a comprender la asocia-ción del FC, con el receptor del gusto dulce (TAS1R2), evidenciando el enlace con componentes moleculares, y su posible relación con adicción a alimentos azucarados.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43484637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We investigated the therapeutic effect of vitamin D (VitD) drops, combined with conventional western medicine (insulin), on children with type 1 diabetes mellitus (T1DM). Eighty-four children with T1DM were divided into a routine group and an observation group (42 cases in each group). The routine group was treated with insulin; while the observation group was treated with insulin plus VitD drops. The serum levels of 25-hydroxyvitamin D3 (25(OH)D3) were compared between the two groups before and after treatment. The daily dosage of insulin, time needed for glucose control, two-hour postprandial blood sugar and frequency of episodes of hypoglycemia, were recorded. Flow cytometry was used to detect and compare interferon gamma (INF-γ), interleukin 4 (IL4), and INF-γ/IL-4 expression in CD4+ T cells of peripheral blood before and after treatment. Complication rates and readmission rates were documented during the six-month follow-ups. VitD drops significantly improved serum vitamin D levels in the routine group (P<0.05). Compared with this group, the daily doses of insulin were lower, the time of blood sugar reaching normal ranges was shorter and the frequency of hypoglycemia was lower in the observation group (P<0.05). There were significant differences in the 2-hour postprandial blood sugar levels, and flow cytometry results between the two groups (P<0.05). VitD drops combined with insulin are beneficial for blood glucose control of children with T1DM, effectively reducing the insulin utilization rate, reducing the frequency of hypoglycemia, and helping to regulate the Th1/Th2 balance disorder. Complementary treatment with this vitamin is safe and reliable, and can reduce the incidence of complications and readmission rates.
{"title":"Effect of vitamin D drops combined with conventional western medicine on children with Type 1 diabetes mellitus","authors":"Jinjun Xue, Jiacong Xuan","doi":"10.22209/ic.v62n2a06","DOIUrl":"https://doi.org/10.22209/ic.v62n2a06","url":null,"abstract":"We investigated the therapeutic effect of vitamin D (VitD) drops, combined with conventional western medicine (insulin), on children with type 1 diabetes mellitus (T1DM). Eighty-four children with T1DM were divided into a routine group and an observation group (42 cases in each group). The routine group was treated with insulin; while the observation group was treated with insulin plus VitD drops. The serum levels of 25-hydroxyvitamin D3 (25(OH)D3) were compared between the two groups before and after treatment. The daily dosage of insulin, time needed for glucose control, two-hour postprandial blood sugar and frequency of episodes of hypoglycemia, were recorded. Flow cytometry was used to detect and compare interferon gamma (INF-γ), interleukin 4 (IL4), and INF-γ/IL-4 expression in CD4+ T cells of peripheral blood before and after treatment. Complication rates and readmission rates were documented during the six-month follow-ups. VitD drops significantly improved serum vitamin D levels in the routine group (P<0.05). Compared with this group, the daily doses of insulin were lower, the time of blood sugar reaching normal ranges was shorter and the frequency of hypoglycemia was lower in the observation group (P<0.05). There were significant differences in the 2-hour postprandial blood sugar levels, and flow cytometry results between the two groups (P<0.05). VitD drops combined with insulin are beneficial for blood glucose control of children with T1DM, effectively reducing the insulin utilization rate, reducing the frequency of hypoglycemia, and helping to regulate the Th1/Th2 balance disorder. Complementary treatment with this vitamin is safe and reliable, and can reduce the incidence of complications and readmission rates.","PeriodicalId":14514,"journal":{"name":"Investigacion clinica","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42672129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：